Chemcrux Enterprises Limited is an established Indian manufacturer specializing in high-value intermediates for **Active Pharmaceutical Ingredients (APIs), Dyes, and Pigments**. Founded in **1983**, the company has evolved from a small-scale unit into a technically sophisticated player in the specialty chemicals space, recognized for its expertise in complex, high-pressure chemical reactions. --- ### **Core Manufacturing Capabilities & Process Expertise** The company’s competitive advantage is rooted in its mastery of hazardous and complex chemical processes. Chemcrux operates primarily in the manufacturing of **Bulk Drug Intermediates**, focusing on **Chloro Nitro Benzoic acids** and **amide derivatives**. **Key Chemical Competencies:** * **High-Pressure Oxidation** * **Nitration and Chlorosulfonation** * **Amidation** * **Continuous Process Technologies:** Implementation of these processes has led to a **significant reduction in energy consumption** and shorter lead times. **Research & Development (R&D):** The company operates an in-house R&D facility in **Ankleshwar, Gujarat**, focused on indigenous technology development and import substitution. Notably, Chemcrux has **not imported any technology** in the last three years, relying entirely on internal innovation. | R&D Expenditure (FY 2024-25) | Amount (₹ in Lakhs) | | :--- | :--- | | **Revenue Expenditure** | **13.85** | | **Capital Expenditure** | **Nil** | | **Total R&D Investment** | **13.85** | --- ### **Strategic Infrastructure & Capacity Expansion** Chemcrux has recently undergone a transformative expansion phase to capitalize on the global **"China + 1"** sourcing strategy and the **"Make in India"** initiative. * **Ankleshwar Plant Expansion:** The company doubled its reaction capacity to **250 KL** at its primary facility. Commercial production from this expanded capacity commenced on **August 16, 2024**. * **Logistics Support:** A new **warehouse facility** was commissioned to support the increased throughput. * **Operational Footprint:** * **Manufacturing:** GIDC Ankleshwar, Gujarat (Core production of Para Chloro Benzoic and Lasamide). * **Subsidiary Plant:** Moksi, Savli, Vadodara (Operated by Kalichem Private Limited). * **Corporate Office:** Vadodara, Gujarat. --- ### **Corporate Structure & Strategic Integration** The company has transitioned toward a more integrated corporate structure to secure its supply chain and enhance market reach. * **Full Acquisition of Kalichem:** Effective **February 27, 2025**, Chemcrux acquired the remaining **50% stake** in its joint venture, **Kalichem Private Limited**, making it a **100% subsidiary**. Kalichem began commercial production in **November 2024**. * **Deepak Nitrite Collaboration:** In **FY 2025-26**, the company entered a strategic collaboration with **Deepak Nitrite Limited** to improve cost competitiveness and supply chain efficiency. * **Product Portfolio Expansion:** In May 2025, the company signed an **Exclusive Purchase and Marketing Agreement** for **Para Nitro Benzoic Acid (PNBA)** to bolster its market presence. --- ### **Financial Performance & Capital Management** Chemcrux migrated from the **BSE SME Platform** to the **Main Board** in **May 2022**, reflecting its growth in scale and governance standards. **Financial Summary:** | Particulars (₹ in Lakhs) | FY 2024-25 (Consolidated) | FY 2023-24 (Standalone) | FY 2022-23 (Standalone) | | :--- | :---: | :---: | :---: | | **Revenue from Operations** | - | **7,846.53** | **9,515.24** | | **Profit After Tax (PAT)** | - | **844.43** | **1,435.81** | | **Total Equity** | **7,462.26** | **7,225.85** | **6,640.58** | | **Gross Debt** | **4,152.79** | **2,554.64** | **1,341.53** | | **Net Debt to Equity Ratio** | **0.56** | **0.35** | **0.20** | **Capital & Liquidity Details:** * **Share Capital:** The company is increasing its **Authorised Share Capital** from **₹15 Crores** to **₹20 Crores**. * **Dividends:** A final dividend of **10% (₹1 per share)** was recommended for FY 2024-25. * **Debt Profile:** Funding is secured through **Kotak Mahindra Bank** (Interest at **9.25%**) and **AU Small Finance Bank** (Interest at **10.00%**). The **Debt-to-Equity ratio** rose to **0.56** in 2025 due to aggressive expansion funding. * **Employee Incentives:** The **'ESOP 2025'** scheme was launched with approval to issue up to **20,00,000 shares** to retain key technical talent. --- ### **Sustainability & Operational Efficiency** The company integrates ESG (Environmental, Social, and Governance) principles into its operational framework, holding **ISO 9001, 14001, and 50001** certifications. * **Energy Management:** In FY 2024-25, the company achieved a **15% reduction** in utility costs per kg of production. * **Sustainability Rating:** Rated **'Committed'** by **EcoVadis**. * **Utility Profile (FY 2024-25):** * Grid Energy: **3,995 MWh** (Cost: **₹3.32 crore**). * Self-Generated Power: **61,629.6 units** (Cost: **₹18.95 Lakhs**). --- ### **Risk Profile & Regulatory Compliance** As a manufacturer in the chemical sector, Chemcrux navigates a complex landscape of environmental and market risks. **1. Environmental & Regulatory Oversight:** * **GPCB Compliance:** In **September 2025**, the **Gujarat Pollution Control Board (GPCB)** issued a temporary closure direction for the Ankleshwar plant. Operations resumed on **September 30, 2025**, following compliance. * **Emission Incidents:** The company paid a **₹9,00,000** penalty in **August 2025** related to a **NOx emission** leak. * **Labour Reforms:** Management is currently assessing the financial impact of the four new **Labour Codes** effective as of **November 2025**. **2. Market & Macroeconomic Risks:** * **Chinese Competition:** The company faces aggressive pricing and "dumping" from Chinese manufacturers. * **Input Volatility:** Exposure to **crude oil** price fluctuations and global supply chain disruptions caused by the **Russia-Ukraine war**. * **Currency Exposure:** The company is exposed to the **USD**. A **5% weakening of the INR** would impact profits by approximately **₹6.22 Lakhs**. As of March 2025, **no forward contracts** were in place to hedge this risk. **3. Financial & Managerial Constraints:** * **Remuneration Caps:** Due to current profit scales, the company noted that it could not pay full managerial remuneration to all Executive Directors under the **Section 197** cap, highlighting the urgent need for the recent capacity expansions to translate into higher turnover. * **Goodwill Impairment:** Following the acquisition of **Kalichem**, the company recognized an impairment on goodwill due to initial losses of **₹2.35 Crores** incurred by the subsidiary during its ramp-up phase.